Breast cancer in adolescents and young women

European Journal of Cancer

Volumn 39, Issue 18, 2003, Pages 2632-2642

  Shannon, C ^a   Smith, I E ^b  

^a MATER ADULT HOSPITAL   (Australia)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Adolescents; Breast cancer; Management; Psychosocial issues

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; METHOTREXATE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AMENORRHEA; BREAST CARCINOMA; BREAST SURGERY; CANCER CELL; CANCER SURGERY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; EMOTIONAL STRESS; FEMALE; FEMALE INFERTILITY; FOLLOW UP; GENE MUTATION; GERM LINE; HORMONAL THERAPY; HUMAN; LYMPH VESSEL; MENOPAUSE; ONCOGENE; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; TERATOGENICITY;

EID: 0344120863     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00669-5     Document Type: Article

References (106)

1. Surveillance E, and End Results (SEER) Program Public-Use CD-ROM (1973-1997). National Cancer Institute, DCCPS, Cancer Surveillance Research Program, Cancer Statistics Branch, released April 2000, based on August 1999 submission. In; 2000.
2. Bothroyd A.C.H. Breast masses in childhood and adolescence. Pediatr. Radiol. 24:1994;81-85.
3. Ferguson T.B.M.K., Filston H.C. Juvenile secretory carcinoma and juvenile papillomatosis. diagnosis and treatment J. Pediatr. Surg. 22:1987;637-639.
4. Karl S.R.B.T., Zaino R. Juvenile secretory carcinoma of the breast. J. Pediatr. Surg. 20:1985;368-371.
5. Swanson G.M., Lin C.S. Survival patterns among younger women with breast cancer. the effects of age, race, stage, and treatment J. Natl. Cancer Inst. Monogr. 16:1994;69-77.
6. Rosen P.P.C.M. Secretory carcinoma of the breast. Arch Pathol. Lab. Med. 115:1991;141-144.
7. Serour F.G.A., Kopolovic J.et al. Secretory breast cancer in childhood and adolescence. report of a case and review of the literature Med. Pediatr. Oncol. 20:1992;341-344.
8. Aebi S., Gelber S., Castiglione-Gertsch M.et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet. 355:2000;1869-1874.
9. Walker R.A., Lees E., Webb M.B., Dearing S.J. Breast carcinomas occurring in young women (<35 years) are different. Br. J. Cancer. 74:1996;1796-1800.
10. Winchester D.P., Osteen R.T., Menck H.R. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer. 78:1996;1838-1843.
11. Kollias J.E.C., Ellis I.O., Robertson J.F., Blamey R.W. Early-onset breast cancer. histopathological and prognostic consideration Br. J. Cancer. 75:1997;1318-1323.
12. Chung M., Chang H.R., Bland K.I., Wanebo H.J. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 77:1996;97-103.
13. Adami H.O., Malker B., Holmberg L., Persson I., Stone B. The relation between survival and age at diagnosis in breast cancer. N. Engl. J. Med. 315:1986;559-563.
14. Albain K.S., Allred D.C., Clark G.M. Breast cancer outcome and predictors of outcome. are there age differentials? J. Natl. Cancer Inst. Monogr. 16:1994;35-42.
15. Holli K.I.J. Effect of age on the survival of breast cancer patients. Eur. J. Cancer. 33:1997;425-428.
16. Kroman N., Jensen M.B., Wohlfahrt J., Mouridsen H.T., Andersen P.K., Melbye M. Factors influencing the effect of age on prognosis in breast cancer. population based study Br. Med. J. 320:2000;474-478.
17. Host H.L.E. Age as a prognostic factor in breast cancer. Cancer. 57:1986;2217-2221.
18. De La Rochefordiere A.A.B., Campana F., Scholl S.M.et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet. 341:1993;1039-1043.
19. Nixon A.J., Neuberg D., Hayes D.F.et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J. Clin. Oncol. 12:1994;888-894.
20. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Senn H.J. Meeting highlights. International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer J. Clin. Oncol. 19:2001;3817-3827.
21. National Institutes of Health Consensus Development Conference Statement. Adjuvant Therapy for breast cancer, November 1-3, 2000 J. Natl. Cancer Inst. 30:2001;5-15.
22. Gajdos C., Tartter P.I., Bleiweiss I.J., Bodian C., Brower S.T. Stage 0 to stage III breast cancer in young women. J. Am. Coll. Surg. 190:2000;523-529.
23. Elkhuizen P.H., van de Vijver M.J., Hermans J., Zonderland H.M., van de Velde C.J., Leer J.W. Local recurrence after breast-conserving therapy for invasive breast cancer. high incidence in young patients and association with poor survival Int. J. Radiat. Oncol. Biol. Phys. 40:1998;859-867.
24. Haffty B.G., Fischer D., Rose M., Beinfield M., McKhann C. Prognostic factors for local recurrence in the conservatively treated breast cancer patient. a cautious interpretation of the data J. Clin. Oncol. 9:1991;997-1003.
25. Kurtz J.M., Jacquemier J., Amalric R.et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients? J. Clin. Oncol. 8:1990;591-598.
26. Arriagada R., Le M.G., Contesso G., Guinebretiere J.M., Rochard F., Spielmann M. Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann. Oncol. 13:2002;1404-1413.
27. Voogd A.C., Nielsen M., Peterse J.L.et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer. pooled results of two large European randomized trials J. Clin. Oncol. 19:2001;1688-1697.
28. Schag C.A., Ganz P.A., Polinsky M.L., Fred C., Hirji K., Petersen L. Characteristics of women at risk for psychosocial distress in the year after breast cancer. J. Clin. Oncol. 11:1993;783-793.
29. Bloom J.R., Kessler L. Risk and timing of counselling and support interventions for younger women with breast cancer. J. Natl. Cancer Inst. Monogr. 16:1994;199-206.
30. Roberts C.S., Cox C.E., Reintgen D.S., Baile W.F., Gibertini M. Influence of physician communication on newly diagnosed breast patients' psychologic adjustment and decision-making. Cancer. 74(Suppl. 1):1994;336-341.
31. Roberts C.S., Cox C.E., Shannon V.J., Wells N.L. A closer look at social support as a moderator of stress in breast cancer. Health Soc. Work. 19:1994;157-164.
32. Neuling S.J., Winefield H.R. Social support and recovery after surgery for breast cancer. frequency and correlates of supportive behaviours by family, friends and surgeon Soc. Sci. Med. 27:1988;385-392.
33. Ashley S., Royle G.T., Corder A.et al. Clinical, radiological and cytological diagnosis of breast cancer in young women. Br. J. Surg. 76:1989;835-837.
34. Brand I.R., Sapherson D.A., Brown T.S. Breast imaging in women under 35 with symptomatic breast disease. Br. J. Radiol. 66:1993;394-397.
35. Kothari A.S., Beechey-Newman N., D'Arrigo C.et al. Breast carcinoma in women age 25 years or less. Cancer. 94:2002;606-614.
36. Hochman M.G., Orel S.G., Powell C.M., Schnall M.D., Reynolds C.A., White L.N. Fibroadenomas. MR imaging appearances with radiologic-histopathologic correlation Radiology. 204:1997;123-129.
37. Colleoni M., Rotmensz N., Robertson C.et al. Very young women (<35 years) with operable breast cancer. features of disease at presentation Ann. Oncol. 13:2002;273-279.
38. Dubsky P.C., Gnant M.F., Taucher S.et al. Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin. Breast Cancer. 3:2002;65-72.
39. Xiong Q., Valero V., Kau V.et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis. the M.D. Anderson Cancer Center experience Cancer. 92:2001;2523-2528.
40. Goldhirsch A., Gelber R.D., Yothers G.et al. Adjuvant therapy for very young women with breast cancer. need for tailored treatments J. Natl. Cancer Inst. Monogr. 30:2001;44-51.
41. Kurtz J.M., Spitalier J.M., Amalric R.et al. Mammary recurrences in women younger than forty. Int. J. Radiat. Oncol. Biol. Phys. 15:1988;271-276.
42. Calle R., Vilcoq J.R., Zafrani B., Vielh P., Fourquet A. Local control and survival of breast cancer treated by limited surgery followed by irradiation. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;873-878.
43. van Limbergen E., van den Bogaert W., van der Schueren E., Rijnders A. Tumor excision and radiotherapy as primary treatment of breast cancer. Analysis of patient and treatment parameters and local control. Radiother. Oncol. 8:1987;1-9.
44. Kini V.R., White J.R., Horwitz E.M., Dmuchowski C.F., Martinez A.A., Vicini F.A. Long term results with breast-conserving therapy for patients with early stage breast carcinoma in a community hospital setting. Cancer. 82:1998;127-133.
45. Stotter A.T., McNeese M.D., Ames F.C., Oswald M.J., Ellerbroek N.A. Predicting the rate and extent of locoregional failure after breast conservation therapy for early breast cancer. Cancer. 64:1989;2217-2225.
46. Fowble B.L., Schultz D.J., Overmoyer B.et al. The influence of young age on outcome in early stage breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 30:1994;23-33.
47. Borger J., Kemperman H., Hart A., Peterse H., van Dongen J., Bartelink H. Risk factors in breast-conservation therapy. J. Clin. Oncol. 12:1994;653-660.
48. Voogd A.C., Peterse J.L., Crommelin M.A.et al. Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on local Recurrence after Breast Conservation (BORST). Eur. J. Cancer. 35:1999;1828-1837.
49. Schnitt S.J., Connolly J.L., Harris J.R., Hellman S., Cohen R.B. Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy. Cancer. 53:1984;1049-1057.
50. Osteen R.T., Connolly J.L., Recht A., Silver B., Schnitt S.J., Harris J.R. Identification of patients at high risk for local recurrence after conservative surgery and radiation therapy for stage I or II breast cancer. Arch. Surg. 122:1987;1248-1252.
51. Veronesi U., Marubini E., Del Vecchio M.et al. Local recurrences and distant metastases after conservative breast cancer treatments. partly independent events J. Natl. Cancer Inst. 87:1995;19-27.
52. Fourquet A., Campana F., Zafrani B.et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer. a 25-year follow-up Int. J. Radiat. Oncol. Biol. Phys. 17:1989;719-725.
53. Anscher M.S., Jones P., Prosnitz L.R.et al. Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy. Ann. Surg. 218:1993;22-28.
54. Dewar J.A., Arriagada R., Benhamou S.et al. Local relapse and contralateral tumor rates in patients with breast cancer treated with conservative surgery and radiotherapy (Institut Gustave Roussy 1970-1982). IGR Breast Cancer Group. Cancer. 76:1995;2260-2265.
55. Schnitt S.J., Abner A., Gelman R.et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer. 74:1994;1746-1751.
56. Macmillan R.D., Purushotham A.D., Mallon E., Love J.G., George W.D. Tumour bed positivity predicts outcome after breast-conserving surgery. Br. J. Surg. 84:1997;1559-1562.
57. Polychemotherapy for early breast cancer. an overview of the randomised trials Lancet. 352:1998;930-942.
58. Tamoxifen for early breast cancer. an overview of the randomised trials Lancet. 351:1998;1451-1467.
59. Levine M.N., Bramwell V.H., Pritchard K.I.et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 16:1998;2651-2658.
60. Henderson I.C., Berry D.A., Demetri G.D.et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21:2003;976-983.
61. Mamounas E.P.B.J., Lembersky B.C., Fisher B.et al. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc. Am. Soc. Clin. Oncol. 22:2003;4.
62. Nabholtz J.M.P.T., Mackey J., Pawlicki M.et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients. interim analysis of the BCIRG 001 study Proc. Am. Soc. Clin. Oncol. 2002;2136a.
63. Citron M., Berry D.A., Cirroncione C.et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer. first report of Intergroup trial C9741/Cancer and Leukemia group B trial 9741 J. Clin. Oncol. 21:2003;1431-1439.
64. Goldhirsch A., Gelber R.D., Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann. Oncol. 1:1990;183-188.
65. Bianco A.R., Del Mastro L., Gallo C.et al. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br. J. Cancer. 63:1991;799-803.
66. Jonat W. Zoladex versus CMF adjuvant therapy in pre/peri-menopausal breast cancer. tolerability and amenorrhea comparisons Proc. Am. Soc. Clin. Oncol. 19:2000;87a.
67. Richards M.A., O'Reilly S.M., Howell A.et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer. an update of the Guy's/Manchester trial J. Clin. Oncol. 8:1990;2032-2039.
68. Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M., Hood N. Risk of menopause during the first year after breast cancer diagnosis. J. Clin. Oncol. 17:1999;2365-2370.
69. Boccardo F., Rubagotti A., Amoroso D.et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients. results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it J. Clin. Oncol. 18:2000;2718-2727.
70. Jakesz R., Hausmaninger H., Kubista E.et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil. evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5 J. Clin. Oncol. 20:2002;4621-4627.
71. Jonat W., Kaufmann M., Sauerbrei W.et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer. the Zoladex Early Breast Cancer Research Association Study J. Clin. Oncol. 20:2002;4628-4635.
72. Davidson N.E.O.N.A., Vukov A.et al. Effect of chemohormonal therapy in premenopausal, node+, receptor+ breast cancer. an Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101) Proc. Am. Soc. Clin. Oncol. 18:1999;67a.
73. Bines J., Oleske D., Cobleigh M. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 14:1996;1718-1729.
74. Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk. Lymph. 33:1999;65-76.
75. Del Mastro L., Venturini M., Sertoli M.R., Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients. prognostic role and clinical implications Breast Cancer Res. Treat. 43:1997;183-190.
76. Lower E., Blau R., Gazder P., Tummala R. The risk of premature menopause induced by chemotherapy for early breast cancer. J. Womens Health Gen. Based Med. 8:1999;949-954.
77. Hortobagyi G.N., Buzdar A.U., Marcus C.E., Smith T.L. Immediate and long-term of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1:1986;105-109.
78. Fox K., Ball J.E., Mick R., Moor H.C.F. Prevention of chemotherapy-associated amenorrhoea with Leuprolide in young women with early-stage breast cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;25a.
79. Recchia F., Sica G., De Filippis S., Saggio G., Rosselli M., Rea S. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer. a phase II pilot study Anticancer Drugs. 13:2002;417-424.
80. Lishner M. Cancer in pregnancy. Ann. Oncol. 14(Suppl. 3):2003;31-36.
81. MH Max T.K. Pregnancy and breast cancer. South Med. J. 76:1983;1088-1090.
82. Zemlickis D.L.M., Degenforfer P. Maternal and fetal outcome after breast cancer in pregnancy. Am. J. Obstet. Gynecol. 166:1992;781-787.
83. Clark R.M., Reid J. Carcinoma of the breast in pregnancy and lactation. Int. J. Radiat. Oncol. Biol. Phys. 4:1978;693-698.
84. Bonnier P., Romain S., Dilhuydy J.M. Influence of pregnancy on the outcome of breast cancer. a case-control study Int. J. Cancer. 72:1997;751-755.
85. Petrek J. Breast cancer during pregnancy. Cancer. 74:1994;518-527.
86. Doll D. Antineoplastic agents and pregnancy. Semin. Oncol. 16:1989;337-346.
87. Tretli S.K.G., Thoreson S. Survival of breast cancer patients diagnosed during pregnancy and lactation. Br. J. Cancer. 58:1988;382-384.
88. Difronzo L.A.O.C.T. Breast cancer in pregnancy and lactation. Surg. Clin. North. Am. 76:1996;267-278.
89. Gelber S., Coates A.S., Goldhirsch A.et al. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J. Clin. Oncol. 19:2001;1671-1675.
90. Northouse L.L. Breast cancer in younger women. effects on interpersonal and family relations J. Natl. Cancer Inst. Monogr. 16:1994;183-190.
91. Farash J. Effect of counselling on resolution of loss and body image following a mastectomy. Diss Abstr Int. 39:1979;4027B.
92. Lee P. The psychological impact of cancer. an evaluation of laryngectomy, mastectomy and ostomy rehabilitation service programs for cancer patients Dis Abstr Int. 41:1981;3625B.
93. Van den Borne H., Pruyn J., Van den Heuvel W.J. Effects of contracts between cancer patients on their psychosocial problems. Patient Educ Counsell. 1:1987;33-51.
94. Schain W.S., d'Angelo T.M., Dunn M.E., Lichter A.S., Pierce L.J. Mastectomy versus conservative surgery and radiation therapy. Psychosocial consequences. Cancer. 73:1994;1221-1228.
95. Council NHaMR. Familial Aspects of Cancer: A Guide to Clinical Practice. Commonwealth of Australia, Canberra, 1999.
96. Easton D.F., Ford D., Bishop D.T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 56:1995;265-271.
97. Li F.P., Fraumeni J.F. Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med. 71:1969;747-752.
98. Nelen M.R., Padberg G.W., Peeters E.A.et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat. Genet. 13:1996;114-116.
99. Miller A. Screening by breast self examination. Jatoi I. Breast Cancer Screening. 1997;Springer, New York.
100. Burke W., Daly M., Garber J.et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. Jama. 277:1997;997-1003.
101. Kerlikowske K., Grady D., Rubin S.M., Sandrock C., Ernster V.L. Efficacy of screening mammography. A meta-analysis. Jama. 273:1995;149-154.
102. Robson M.E., Morris E., Kauff N.et al. Breast cancer screening utilizing magnetic resonance imaging (MRI) in carriers of BRCA mutations. Proc. Am. Soc. Clin. Oncol. 22:2003;91.
103. Kuhl C.K., Schrading S., Leutner C.C. Surveillance of "high risk" women with proven or suspected familial (hereditary) breast cancer. first mid-term results of a multi-modality clinical screening trial Proc. Am. Soc. Clin. Oncol. 22:2003;2.
104. Kriege M., Brekelmans C.T.M., Boetes C.et al. MRI screening for breast cancer in women with high familial and genetic risk. first results of the Dutch MRI screening study (MRISC) Proc. Am. Soc. Clin. Oncol. 22:2003;2.
105. Diller L., Medeiros Nancarrow C., Shaffer K.et al. Breast cancer screening in women previously treated for Hodgkin's disease. a prospective cohort study J. Clin. Oncol. 20:2002;2085-2091.
106. Bhatia S., Robison L.L., Oberlin O.et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N. Engl. J. Med. 334:1996;745-751.